Log In
Print
BCIQ
Print
Print this Print this
 

Apokyn, apomorphine hydrochloride

  Manage Alerts
Collapse Summary General Information
Company Stada Arzneimittel AG
DescriptionApomorphine hydrochloride injection
Molecular Target Dopamine receptor
Mechanism of ActionDopamine receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat diurnal variation of symptoms in Parkinson's disease (PD) when usual drug therapy is not sufficient; Treat episode motor symptoms associated with advanced Parkinson's disease (PD); Treat hyperanakinesia caused by Parkinson's disease (PD) related motion complications; Treat Parkinson's disease (PD)
Regulatory Designation Japan - Orphan Drug (Treat diurnal variation of symptoms in Parkinson's disease (PD) when usual drug therapy is not sufficient)
Partner Kyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$10.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today